Test ID: HPFH Hemoglobin F Distribution, Blood
Reporting Name
Hb F Distribution, BUseful For
Distinguishing large deletional hereditary persistence of fetal hemoglobin from other conditions with increased percentage of fetal hemoglobin (HbF)
Determining the distribution of HbF within red blood cells
Specimen Type
Whole Blood EDTAOrdering Guidance
This test is for hereditary persistence of fetal hemoglobin only. For testing for possible fetal-maternal bleed, see FMB / Fetomaternal Bleed, Flow Cytometry, Blood.
Specimen Required
Only orderable as a reflex. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood
-MEV1 / Methemoglobinemia Evaluation, Blood
-REVE2 / Erythrocytosis Evaluation, Blood
-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Whole Blood EDTA | Refrigerated | 14 days |
Reference Values
Only orderable as a reflex. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood
-MEV1 / Methemoglobinemia Evaluation, Blood
-REVE2 / Erythrocytosis Evaluation, Blood
-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum
Reported as: Heterocellular, Homocellular, or Equivocal
Day(s) Performed
Monday through Friday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88184
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HPFH | Hb F Distribution, B | 4579-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 8270 | Hb F Distribution, B | 4579-9 |
| 2104 | Interpretation | 59466-3 |
Clinical Information
More than 75% of the hemoglobin in a newborn infant is fetal hemoglobin (HbF); it diminishes over a period of several months to adult levels, reducing to less than 2% by 1 year of age and less than 1% by 2 years of age.
Hemoglobin F may constitute 90% of the total Hb in patients with beta-thalassemia major or other combinations of beta thalassemia and fetal Hb (hereditary persistence of fetal hemoglobin: HPFH) variants.
Hemoglobin F is often mildly to moderately elevated in sickle cell disease, aplastic anemia, acute leukemia, and myeloproliferative disorders, such as juvenile myelomonocytic leukemia, hereditary spherocytosis, and alpha-thalassemia minor. It is commonly increased in hemoglobinopathies associated with hemolysis. HbF increases to as high as 10% during normal pregnancy. HbF is also increased due to medications such as hydroxyurea, decitabine, and lenalidomide. Elevation in HbF has a been cited as a discriminator between Diamond-Blackfan congenital pure red cell aplasia (elevated) and transient erythroblastopenia of childhood (normal), but whether this simply reflects the chronicity of anemia inherent to the former condition rather than a specific finding is unclear.
In the common (large deletional) form of the genetic trait HPFH, all erythrocytes contain HbF. When tested by flow cytometry using specificity for HbF, these HPFH cases display a homocellular distribution pattern of HbF within the red blood cell population. Other causes of increased HbF, including delta beta thalassemia, hydroxyurea, and some nondeletional HPFH variants, typically display a heterocellular distribution of HbF within the erythrocytes, reflecting disparate populations of F cells and cells lacking HbF. Quantification of HbF percentage should be determined prior to flow cytometry of HbF red blood cell distribution to establish the appropriateness of this test. The flow cytometry analysis of elevated HbF levels is useful when HbF percentage is 15% to 35% and the clinical differential diagnosis includes large deletional HPFH. HbF percentages below 15% are likely not due to large deletional HPFH, and the causes of HbF percentages above 35% are better confirmed by molecular and family studies.
Interpretation
Homocellular distribution of fetal hemoglobin (HbF) is found in large deletional hereditary persistence of HbF.
Heterocellular distribution is found in delta beta thalassemia, medication induced, and other causes of increased HbF.
An equivocal result indicates the pattern is not typical for either a homocellular or heterocellular distribution.
Clinical Reference
1. Kleihauer E, Braun H, Betke K. Demonstration von fetalem Hamoglobin in den Erythrocyten eines Blutaustrichs. Klin Wschr. 1957;35(12):637-638
2. Shepard MK, Weatherall DJ, Conley CC. Semi-quantitative estimation of the distribution of fetal hemoglobin in red cell populations. Bull Johns Hopkins Hospital. 1962;110:293-310
3. Davis BH, Olsen S, Bigelow NC, Chen JC. Detection of fetal red cells in fetomaternal hemorrhage using a fetal hemoglobin monoclonal antibody by flow cytometry. Transfusion. 1998;38(8):749-756
4. Hoyer JD, Penz CS, Fairbanks VF, et al. Flow cytometric measurement of hemoglobin F in RBCs: diagnostic usefulness in the distinction of hereditary persistence of fetal hemoglobin (HPFH) and hemoglobin S-hPFH from other conditions with elevated levels of hemoglobin F. Am J Clin Pathol. 2002;117(6):857-863
5. Stephens AD, Angastiniotis M, Baysal E, et al. International Council for The Standardisation of Haematology (ICSH). ICSH recommendations for the measurement of haemoglobin F. Int J Lab Hematol. 2012;34(1):14-20
6. Khandros E, Blobel GA. Heterogeneity of fetal hemoglobin production in adult red blood cells. Curr Opin Hematol. 2021;28(3):164-170
Report Available
3 to 5 daysMethod Name
Only orderable as a reflex. For more information see:
-HAEV1 / Hemolytic Anemia Evaluation, Blood
-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood
-MEV1 / Methemoglobinemia Evaluation, Blood
-REVE2 / Erythrocytosis Evaluation, Blood
-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum
Flow Cytometry
Specimen Minimum Volume
0.5 mL
mml-benign-hematology-disorders